NCT07201376: Assessment of Skin Lesions Using a Tissue Oxygen Imager Based on Protoporphyrin IX (PPIX) Fluorescence. This is an Open-label, Non-randomized, Feasibility Study That Includes a One-time Application of an FDA Approved Medication Followed by Local Imaging for Benign Skin Growth and Lesions Clinically

Sponsor: Dartmouth-Hitchcock Medical Center. Phase: . Conditions: Non-Melanoma Skin Cancer (NMSC), Benign Skin Growth